Les communiqués de presse contenus dans cette section d’archives sont fournis à des fins historiques uniquement. Les renseignements contenus dans chaque communiqué de presse ne sont exacts qu’à la date de leur publication originale respective. NOXXON rejette toute obligation de mise à jour des renseignements contenus dans ces communiqués de presse après leur date de publication.

Filtres: NOX-E36 (emapticap)NOX-A12 (olaptesed) | NOX-H94 (lexaptepid) | tous

DateTitelDownload

2017,Février 10NOXXON Pharma annonce la nomination du Dr. Jarl Ulf Jungnelius, oncologue spécialiste, au poste de directeur médical

2017, Janvier 06Bilan semestriel du contrat de liquidité contracté avec INVEST securities

2017, Janvier 04NOXXON PHARMA signe avec APTARION biotech un contrat de licence et de cession de ses programmes précliniques

2016, Décembre 15NOXXON Pharma signe un accord de collaboration en immuno-oncologie avec MSD pour réaliser une étude clinique sur NOX-A12 associé au Keytruda (pembrolizumab) dans le cancer du pancréas et le cancer coloretal

2016, Décembre 05NOXXON Pharma annonce de nouvelles données précliniques mettant en évidence une synergie entre NOX-A12 et les thérapies utilisant les cellules tueuses naturelles NK

2016, Octobre 31NOXXON annonce ses resultats semestriels 2016

2016, Octobre 24NOXXON annonce la mise en oeuvre d'un contrat de liquidite avec invest securities

2016, Octobre 10NOXXON Pharma demontre l'existence de synergies entre NOX-A12 et les therapies exploitant les cellules T ou les cellules tueuses naturelles NK

2016, Septembre 28NOXXON Pharma lance la cotation de ses actions sur Alternex Paris

2016, January 20NOXXON Pharma hosts key opinion leader symposium

2015, July 14NOXXON appoints Aram Mangasarian as CEO

2015, May 29First Data from NOXXOs NOX-H94 (Lexaptepid Pegol) Clinical Trial in ESA-Hyporesponsive Dialysis Patients Reported at ERA-EDTA Conference

2015, April 23Nature Communications Publications on the First X-ray Crystal Structures of Spiegelmers Bound to Protein Targets

2014, December 10New Addition to NOXXON Supervisory Board Brings Significant US Public Market Expertise

2014, December 05Phase IIa Results for Spiegelmer Olaptesed Pegol (NOX-A12) in MM and CLL at 2014 American Society of Hematology (ASH) Conference

2014, September 26Cell Reports Publication on the Mechanism of Action of NOXXONs Anti-SDF-1 Spiegelmer Olaptesed Pegol (NOX-A12) in Preclinical Multiple Myeloma Models

2014, September 23NOXXON Spiegelmer receives FDA Orphan Drug Designation for Glioblastoma Treatment

2014, September 18NOXXON Pharma Expands Management Team by Appointing Don Munoz as Chief Financial Officer

2014, September 04Two Presentations at International Conferences of Preclinical Data on NOXXON's anti-C5a Spiegelmer, a Potential Drug in Pneumococcal Pneumonia-Induced Sepsis

2014, July 31NOXXON Initiates Phase IIa Study of Anti-Hepcidin Spiegelmer Lexaptepid Pegol (NOX-H94) in Dialysis Patients with EPO-hyporesponsive Anemia

2014, June 13NOXXON presents Updates on Phase II Studies with Olaptesed Pegol (NOX-A12) in CLL and MM and Lexaptepid Pegol (NOX H94) in Anemic Cancer Patients

2014, June 02NOXXONs Emapticap Pegol Study Selected for Late Breaking Clinical Trials Symposium during ERA-EDTA Conference

2014, April 08Anti-Hepcidin Spiegelmer Lexaptepid Pegol Increases Hemoglobin in Subset of Anemic Patients in Pilot Phase IIa Study

2014, April 04NOXXON presents Positive Results from Emapticap Pegol Phase IIa Diabetic Nephropathy Study

2013, December 09NOXXON presenting at ASH 2013

2013, July 24NOXXON Pharma Completes Patient Recruitment for Phase IIa Study in Diabetic Nephropathy

2012, December 04NOXXON Initiates Phase IIa of Anti-Hepcidin Spiegelmer NOX-H94

2012, September 26NOXXON Initiates Phase IIa Trial of anti-CXCL12/SDF-1 Spiegelmer NOX-A12 in Second Oncology Indication: Multiple Myeloma

2012, July 11NOXXON Initiates Phase IIa of anti-CXCL12/SDF-1 Spiegelmer NOX-A12 for Treatment of Chronic Lymphocytic Leukemia

2012, June 19NOXXON Initiates Phase IIa of Spiegelmer NOX-E36 for Treatment of Diabetic Nephropathy

2012, April 4NOXXONs NOX-A12 Delays Glioblastoma Recurrence in Preclinical Model

2012, January 6NOXXON to Present at 30th Annual J.P. Morgan Healthcare Conference

2011, December 12NOXXONs SDF-1 inhibitor NOX-A12 completes Phase I

2011, September 06NOXXON initiates Phase I of NOX-H94 for Anemia of Chronic Disease

2011, February 03NOXXON Expands Management Team

2010, October 12NOXXON Confirms Total Capital Raise of €35m

2010, September 22NOXXON initiates multiple dose phase I clinical trial of SDF-1 inhibitor NOX-A12

2010, July 7NOXXON to initiate phase Ib clinical trial of MCP-1 inhibitor NOX-E36

2010, June 28NOXXON Pharma AG announces management changes

2010, May 27NOXXON Pharma AG raises €33 million in Series D Round

2010, May 18NOXXON Pharma AG appoints Dr. Aram Mangasarian as Chief Business Officer

2010, May 3NOXXON Announces the Completion of the First-in-Human Clinical Trial with Spiegelmer NOX-A 12

2009, December 3NOXXON Pharma AG Achieves Milestone in Partnership with Eli Lilly and Company

2009, November 2NOXXON Announces Initiation of First-in-Human Clinical Trial with Hematopoietic Stem Cell Mobilizing Spiegelmer NOX-A12

2009, October 12NOXXON announces excellent preliminary phase I trial results for Spiegelmer NOX-E36

2009, September 3NOXXON Is Awarded Research and Development Grant for First-in-Human Clinical Trial with Spiegelmer NOX-A12

2009, June 8NOXXON Announces Initiation of First Clinical Trial with a Spiegelmer

2008, July 8NOXXON Pharma announces appointment of Lawrence E. Posner to its Board of Directors

2008, June 11NOXXON Pharma AG Announces Licensing and Discovery Collaboration with Eli Lilly ...

2008, April 7NOXXON Receives Research Grant from the Federal Ministry of Education and Research

2008, January 7NOXXON Pharma AG appoints Dr. Frank Morich as CEO

2007, November 9NOXXON announces alliance with Roche

2007, June 8NOXXON Pharma announces appointment of Dr. Walter Wenninger as Chairman of the Board

2007, May 3NOXXON Pharma closes Series C Round at Euro 37 million

2007, February 9NOXXON Pharma AG to present at Bio CEO & Investor Conference 2007 in New York

2006, November 3NOXXON Pharma AG to present at Bio-Europe in Duesseldorf, Germany

2006, November 3NOXXON Pharma AG to present at Rodman & Renshaw 8th Annual Healthcare Conference

2006, October 4NOXXON Pharma AG to present at Sachs Associates 6th Annual Biotech in Europe...

2006, May 12NOXXON Pharma AG to present at the Rodman & Renshaw 3rd Annual Global Healthcare...

2006, May 10Change of management at NOXXON Pharma AG

2006, March 23NOXXON Pharma AG announces global strategic alliance with Pfizer. NOX-B11...

2006, March 15NOXXON Pharma AG announces publication of positive animal data with its vasopressin

2006, March 13NOXXON Pharma AG to present at Sachs Associates’ 5th Annual North America Forum...

2006, February 13NOXXON Pharma AG to present at Bio CEO & Investor Conference 2006 in New York